

L.N. 89 of 2020

Dangerous Drugs Ordinance (Amendment of First Schedule) Order 2020

(Made by the Chief Executive under section 50(1) of the Dangerous Drugs Ordinance (Cap. 134) after consultation with the Executive Council)

1. Commencement

This Order comes into operation on 24 July 2020.

2. Dangerous Drugs Ordinance amended

The Dangerous Drugs Ordinance (Cap. 134) is amended as set out in section 3.

3. First Schedule amended

- (1) First Schedule, Part I, paragraph 1(a), after item “Methcathinone (甲卡西酮)”—

Add

“Methoxyacetylfentanyl (甲氧基乙酰芬太尼)”.

- (2) First Schedule, Part I, paragraph 1(a), after item “Methyl 2-([1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate (3,3-二甲基-2-[1-(5-氟戊基)吡唑-3-甲酰氨基]丁酸甲酯)”—

Add

“Methyl 2-([1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl]amino)-3-methylbutanoate (3-甲基-2-([1-[(4-氟苯基)甲基]-1H-吡唑-3-羰基]氨基)丁酸甲酯)”.

Section 3

- (3) First Schedule, Part I, paragraph 1(a), after item “N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (N-(金剛烷-1-基)-1-(5-氟戊基)-1H-吡唑-3-甲酰胺)”—

Add

“N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (N-(1-氨基-3,3-二甲基-1-氧丁烷-2-基)-1-(環己基甲基)-1H-吡唑-3-甲酰胺)

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide (N-(1-氨基-3,3-二甲基-1-氧丁烷-2-基)-1-[(4-氟苯基)甲基]-1H-吡唑-3-甲酰胺)”.

- (4) First Schedule, Part I, paragraph 1(a), after item “4-Cyano-1-methyl-4-phenylpiperidine (4-氰基-1-甲基-4-苯基哌啶)”—

Add

“1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (1-(4-氰基丁基)-N-(2-苯基丙-2-基)-1H-吡唑-3-甲酰胺)”.

Carrie LAM
Chief Executive

15 May 2020

Explanatory Note

This Order amends Part I of the First Schedule to the Dangerous Drugs Ordinance (Cap. 134) in order to impose control on the following substances—

- (a) Methoxyacetylfentanyl;
- (b) Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (commonly known as FUB-AMB);
- (c) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (commonly known as ADB-CHMINACA);
- (d) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide (commonly known as ADB-FUBINACA);
- (e) 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (commonly known as CUMYL-4CN-BINACA).